secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001104659-26-013470
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics requests Type A FDA meeting after CRL for wet AMD drug ONS-5010
--------------------------------------------------------------------------------

- CRL dated Dec 30, 2025 cited lack of substantial evidence; company believes it contradicts alignment from Sept 2025 meeting.
- Phase 3 NORSE TWO met primary endpoint (15-letter gain at 12 months); NORSE EIGHT missed primary at 8 weeks.
- ONS-5010/LYTENAVA is already approved and commercially available in EU and UK for wet AMD.
- FDA has not raised safety concerns; company plans to pursue resolution via Type A meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926013470/0001104659-26-013470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926013470/tm265994d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-013470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer